Barclays initiates Schrodinger stock with Overweight rating on upcoming catalysts

Barclays initiated coverage on Schrodinger (SDGR) with an Overweight rating and a $25 price target, citing two potential Phase 1 clinical trial catalysts for SGR-2921 and SGR-3515 anticipated in Q4 2025, each projected to achieve approximately $150 million in peak probability-adjusted sales by 2035. The firm highlighted SDGR's strong financial position and 18.59% LTM revenue growth. This follows Schrodinger's Q2 2025 earnings beat, where it reported a narrower net loss of $0.65 per share and higher revenue of $54.8 million, though the stock experienced an after-hours decline.

Analysis

Barclays has initiated coverage on Schrodinger (SDGR) with an Overweight rating and a $25.00 price target, representing a notable upside from its current $19.84 price. The valuation is primarily driven by two key catalysts anticipated in Q4 2025: initial Phase 1 data for SGR-2921 and SGR-3515. Each drug is projected to have peak probability-adjusted sales of approximately $150 million by 2035, with Barclays assigning a 70% likelihood of positive data. This presents an asymmetric risk-reward profile, where positive results could add $2 per share for each drug, while negative outcomes could subtract $1-$1.20. Financially, while SDGR is not yet profitable, its balance sheet is robust, featuring more cash than debt and a healthy current ratio of 3.3. This financial stability is complemented by strong top-line growth, evidenced by an 18.59% increase in revenue over the last twelve months. The company's operational strength was recently confirmed by its Q2 2025 earnings report, which surpassed analyst expectations with revenue of $54.8 million (a 5.34% beat) and a net loss of $0.65 per share (an 18.75% positive surprise). Despite these strong fundamental results, the stock declined in after-hours trading, indicating a potential disconnect between the company's performance and immediate market sentiment.

Key Decisions for Investors

• Investors with a higher risk tolerance and a long-term horizon could consider the current valuation an attractive entry point, capitalizing on the disparity between the strong Q2 earnings beat and the subsequent after-hours stock decline.
• The investment thesis is heavily contingent on the binary outcomes of two Phase 1 trials expected in Q4 2025; positions should be managed with a clear understanding of the asymmetric risk profile, where success offers a potential $2 per share upside per drug versus a $1-$1.20 downside on failure.
• Monitor cash burn rate and any pre-clinical updates leading up to the Q4 2025 catalysts, as these will be the primary drivers of valuation and sentiment for this pre-profitability biotech firm.